198 related articles for article (PubMed ID: 25535978)
41. Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia.
Kawata T; Tada K; Kobayashi M; Sakamoto T; Takiuchi Y; Iwai F; Sakurada M; Hishizawa M; Shirakawa K; Shindo K; Sato H; Takaori-Kondo A
Cancer Sci; 2018 Jan; 109(1):103-111. PubMed ID: 29077243
[TBL] [Abstract][Full Text] [Related]
42. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ
Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679
[TBL] [Abstract][Full Text] [Related]
43. mTOR complex 2 is involved in regulation of Cbl-dependent c-FLIP degradation and sensitivity of TRAIL-induced apoptosis.
Zhao L; Yue P; Khuri FR; Sun SY
Cancer Res; 2013 Mar; 73(6):1946-57. PubMed ID: 23319802
[TBL] [Abstract][Full Text] [Related]
44. Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis.
Farhan MA; Carmine-Simmen K; Lewis JD; Moore RB; Murray AG
PLoS One; 2015; 10(8):e0135245. PubMed ID: 26295809
[TBL] [Abstract][Full Text] [Related]
45. Increased milk protein synthesis in response to exogenous growth hormone is associated with changes in mechanistic (mammalian) target of rapamycin (mTOR)C1-dependent and independent cell signaling.
Sciascia Q; Pacheco D; McCoard SA
J Dairy Sci; 2013 Apr; 96(4):2327-2338. PubMed ID: 23462168
[TBL] [Abstract][Full Text] [Related]
46. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
47. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.
Li H; Lin J; Wang X; Yao G; Wang L; Zheng H; Yang C; Jia C; Liu A; Bai X
Breast Cancer Res Treat; 2012 Aug; 134(3):1057-66. PubMed ID: 22476852
[TBL] [Abstract][Full Text] [Related]
48. Mammalian target of rapamycin inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph+ acute lymphoblastic leukemia cells.
Yang X; He G; Gong Y; Zheng B; Shi F; Shi R; Yang X
Eur J Haematol; 2014 Feb; 92(2):111-20. PubMed ID: 24112092
[TBL] [Abstract][Full Text] [Related]
49. An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease.
Ravichandran K; Zafar I; Ozkok A; Edelstein CL
Nephrol Dial Transplant; 2015 Jan; 30(1):45-53. PubMed ID: 25239638
[TBL] [Abstract][Full Text] [Related]
50. MNK1 pathway activity maintains protein synthesis in rapalog-treated gliomas.
Grzmil M; Huber RM; Hess D; Frank S; Hynx D; Moncayo G; Klein D; Merlo A; Hemmings BA
J Clin Invest; 2014 Feb; 124(2):742-54. PubMed ID: 24401275
[TBL] [Abstract][Full Text] [Related]
51. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
Shao H; Gao C; Tang H; Zhang H; Roberts LR; Hylander BL; Repasky EA; Ma WW; Qiu J; Adjei AA; Dy GK; Yu C
J Hepatol; 2012 Jan; 56(1):176-83. PubMed ID: 21835141
[TBL] [Abstract][Full Text] [Related]
52. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
[TBL] [Abstract][Full Text] [Related]
53. Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies.
Gupta M; Hendrickson AE; Yun SS; Han JJ; Schneider PA; Koh BD; Stenson MJ; Wellik LE; Shing JC; Peterson KL; Flatten KS; Hess AD; Smith BD; Karp JE; Barr S; Witzig TE; Kaufmann SH
Blood; 2012 Jan; 119(2):476-87. PubMed ID: 22080480
[TBL] [Abstract][Full Text] [Related]
54. The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.
D'Abronzo LS; Bose S; Crapuchettes ME; Beggs RE; Vinall RL; Tepper CG; Siddiqui S; Mudryj M; Melgoza FU; Durbin-Johnson BP; deVere White RW; Ghosh PM
Oncogene; 2017 Nov; 36(46):6359-6373. PubMed ID: 28745319
[TBL] [Abstract][Full Text] [Related]
55. Reversal effect of PI3-K inhibitor LY294002 on P-glycoprotein-mediated multidrug resistance of human leukemia cell line K562/DNR and gastric cancer cell line SGC7901/ADR.
Zhang Y; Qu XJ; Liu YP; Yang XH; Hou KZ; Teng YE; Zhang JD
Ai Zheng; 2009 Feb; 28(2):97-9. PubMed ID: 19550116
[TBL] [Abstract][Full Text] [Related]
56. Novel Gemini-vitamin D3 analog inhibits tumor cell growth and modulates the Akt/mTOR signaling pathway.
O'Kelly J; Uskokovic M; Lemp N; Vadgama J; Koeffler HP
J Steroid Biochem Mol Biol; 2006 Aug; 100(4-5):107-16. PubMed ID: 16777406
[TBL] [Abstract][Full Text] [Related]
57. Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001.
Kuo SH; Hsu CH; Chen LT; Lu YS; Lin CH; Yeh PY; Jeng HJ; Gao M; Yeh KH; Cheng AL
Eur J Cancer; 2011 May; 47(8):1244-57. PubMed ID: 21334199
[TBL] [Abstract][Full Text] [Related]
58. S6K1 regulates hematopoietic stem cell self-renewal and leukemia maintenance.
Ghosh J; Kobayashi M; Ramdas B; Chatterjee A; Ma P; Mali RS; Carlesso N; Liu Y; Plas DR; Chan RJ; Kapur R
J Clin Invest; 2016 Jul; 126(7):2621-5. PubMed ID: 27294524
[TBL] [Abstract][Full Text] [Related]
59. Ikaros 6 protects acute lymphoblastic leukemia cells against daunorubicin-induced apoptosis by activating the Akt-FoxO1 pathway.
Han J; Jin R; Zhang M; Guo Q; Zhou F
J Leukoc Biol; 2017 Mar; 101(3):675-681. PubMed ID: 27707884
[TBL] [Abstract][Full Text] [Related]
60. Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis.
Wang X; Lai P; Zhang Z; Huang M; Wang L; Yin M; Jin D; Zhou R; Bai X
Oncol Rep; 2014 Jul; 32(1):382-8. PubMed ID: 24840134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
